Recent News
Analysis of 70 Mesothelioma Cases
Malignant pleural mesothelioma is a severe cancer mainly caused by asbestos exposure. It often appears decades after exposure. Early on, symptoms can be unclear, making it difficult to diagnose. Even[…]
Read MorePORT-7 for the Treatment of Mesothelioma
Results from a clinical trial being performed on malignant pleural mesothelioma patients will be presented at the American Association for Cancer Research meeting being held in Chicago, Illinois. Results will[…]
Read MoreAgeing and Mesothelioma
Mesothelioma, a rare and aggressive cancer mainly caused by asbestos exposure, mostly affects the lining of the lungs, but can also affect the lining of the abdomen, heart, and testicles.[…]
Read MoreImmunotherapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There[…]
Read MoreJohnson & Johnson’s Talc Settlement Proposal Denied
A United States Bankruptcy Judge from the Southern District of Texas has denied Johnson & Johnson’s $10 billion baby powder settlement proposal. This is the third time J&J has tried[…]
Read MoreAsbestos Delays Wildfire Cleanup
Asbestos testing with certified asbestos consultants and other experts has been ongoing since two wildfires, Eaton and Palisades, blazed across California in 2025. More properties that were burned in the[…]
Read MoreCAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for[…]
Read MoreAsbestos Tailings Could be Used to Help the Environment
An abandoned asbestos mine in Baie Verte, in Newfoundland, is expected to have a significant environmental remediation project. BAIE Minerals, a company that specializes in mineral upcycling, plans to transform[…]
Read MoreAnti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response[…]
Read MoreSurgeries for Mesothelioma
Pleural mesothelioma is a very rare and aggressive cancer mainly caused by asbestos exposure. The survival time is very low, with people typically surviving around 9 to 20 months after[…]
Read More